...
首页> 外文期刊>Sleep & breathing =: Schlaf & Atmung >Sleepiness as a marker of glucose deregulation in obstructive sleep apnea.
【24h】

Sleepiness as a marker of glucose deregulation in obstructive sleep apnea.

机译:嗜睡是阻塞性睡眠呼吸暂停中葡萄糖失调的标志。

获取原文
获取原文并翻译 | 示例
           

摘要

Excessive daytime sleepiness (EDS) is a major but not universally present feature of obstructive sleep apnea syndrome (OSAS). The latter has been associated with glucose dysmetabolism and insulin resistance. The aim of this study was to examine the role of EDS by investigating potential differences between somnolent and non-somnolent OSAS patients in glucose metabolism, insulin resistance, and levels of cardiovascular risk factors.Included were 25 newly diagnosed otherwise healthy OSAS patients, reporting EDS (ESS ≥ 11) and 25 age- and BMI-matched, non-somnolent (ESS ≤ 10) OSAS patients, who served as controls. Fasting glucose and insulin levels, as well as homeostatic model assessment of insulin resistance (HOMA(IR)) index, levels of hs-CRP, and lipidemic profile were measured.The two groups did not differ in anthropometric or sleep characteristics. A significant correlation of ESS with glucose (p = 0.004), insulin (p = 0.011), and HOMA(IR) (p = 0.031) was observed. Somnolent patients had higher levels of glucose (p = 0.045), insulin (p = 0.012), and HOMA(IR) (p = 0.027). No difference was detected in other markers between the two groups.Daytime sleepiness in OSAS patients is associated with hyperglycemia and hyperinsulinemia. These results suggest its potential use as a surrogate marker of insulin resistance in such patients.
机译:白天过度嗜睡(EDS)是阻塞性睡眠呼吸暂停综合症(OSAS)的主要特征,但并非普遍存在。后者与葡萄糖代谢不良和胰岛素抵抗有关。这项研究的目的是通过调查有能力和非有能力的OSAS患者在糖代谢,胰岛素抵抗和心血管危险因素水平方面的潜在差异来检查EDS的作用,其中包括25例新诊断为健康的OSAS患者,报告了EDS (ESS≥11)和25例年龄和BMI匹配的非声带(ESS≤10)OSAS患者作为对照。空腹血糖和胰岛素水平,以及对胰岛素抵抗(HOMA(IR))指数的稳态模型评估,hs-CRP水平和血脂水平进行了测量。两组的人体测量或睡眠特征无差异。观察到ESS与葡萄糖(p = 0.004),胰岛素(p = 0.011)和HOMA(IR)(p = 0.031)显着相关。睡眠障碍患者的葡萄糖(p = 0.045),胰岛素(p = 0.012)和HOMA(IR)(p = 0.027)较高。两组之间其他指标均无差异。OSAS患者白天嗜睡与高血糖和高胰岛素血症有关。这些结果表明其在此类患者中作为胰岛素抵抗替代指标的潜在用途。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号